Jazz Pharmaceuticals (JAZZ) Enterprise Value (2010 - 2026)

Jazz Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$1.8 billion for Q1 2026.

• In Q1 2026, Enterprise Value rose 0.95% year-over-year to -$1.8 billion; the TTM figure through Mar 2026 stood at -$1.8 billion (up 0.95% YoY), while the FY2025 annual figure was -$1.4 billion, up 42.31% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.8 billion, down from -$1.4 billion in the prior quarter.
• The five-year high for Enterprise Value was -$490.8 million in Q1 2022, with the low at -$2.4 billion in Q4 2024.
• The 5-year median for Enterprise Value is -$1.3 billion (2023), against an average of -$1.4 billion.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value jumped 76.6% in 2022, then slumped 137.94% in 2023.
• Jazz Pharmaceuticals' Enterprise Value stood at -$881.5 million in 2022, then sank by 70.88% to -$1.5 billion in 2023, then slumped by 60.18% to -$2.4 billion in 2024, then jumped by 42.31% to -$1.4 billion in 2025, then tumbled by 32.5% to -$1.8 billion in 2026.
• Business Quant data shows JAZZ's Enterprise Value at -$1.8 billion in Q1 2026, -$1.4 billion in Q4 2025, and -$1.3 billion in Q3 2025.